このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Argenica Therapeutics マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Liz Dallimore

最高経営責任者

AU$424.2k

報酬総額

CEO給与比率	67.8%
CEO在任期間	2.5yrs
CEOの所有権	1.3%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	2.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Argenica Therapeutics の収益と比較して、Liz Dallimore の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	AU$424k	AU$288k	-AU$5m
Mar 31 2024	n/a	n/a	-AU$5m
Dec 31 2023	n/a	n/a	-AU$5m
Sep 30 2023	n/a	n/a	-AU$5m
Jun 30 2023	AU$675k	AU$250k	-AU$5m
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$4m
Sep 30 2022	n/a	n/a	-AU$4m
Jun 30 2022	AU$337k	AU$228k	-AU$4m
Mar 31 2022	n/a	n/a	-AU$3m
Dec 31 2021	n/a	n/a	-AU$3m
Sep 30 2021	n/a	n/a	-AU$2m
Jun 30 2021	AU$145k	AU$31k	-AU$1m

報酬と市場: Lizの総報酬 ($USD 288.49K ) は、 Australian市場 ($USD 305.11K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Lizの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Liz Dallimore

2.5yrs

在職期間

AU$424,246

報酬

Dr. Liz Dallimore (B. Sc. (Hons), MBA, PhD, GAICD) serves as Chief Executive Officer of Argenica Therapeutics Limited ands serves as its Managing Director and Director since April 4, 2022. She is a researc...

取締役

名称	ポジション	在職期間	報酬	所有権
Liz Dallimore	CEO, MD & Director	2.5yrs	AU$424.25k	1.29% A$ 1.2m
Dianne Angus	Non-Executive Chairman	less than a year	AU$102.58k	データなし
Geoffrey Donnan	Member of Clinical Advisory Committee	no data	データなし	データなし
Terence Budge	Independent Non-Executive Director	3.8yrs	AU$44.40k	0.63% A$ 580.1k
Elizabeth McCall	Independent Non-Executive Director	3.8yrs	AU$44.40k	0.35% A$ 319.1k
Robert Black	Non-Executive Director	less than a year	データなし	0.020% A$ 18.0k
Paul Bailey	Member of Clinical Advisory Committee	no data	データなし	データなし
Tim Phillips	Member of Clinical Advisory Committee	no data	データなし	データなし
David Blacker	Chairman of Clinical Advisory Committee	no data	データなし	データなし
Jeffery Saver	Member of Clinical Advisory Committee	2.3yrs	データなし	データなし
Mark Etherton	Non-Executive Director	less than a year	データなし	データなし

2.3yrs

平均在職期間

経験豊富なボード: AGNの取締役会は経験豊富ではない ( 2.2年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Argenica Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 24, 2022

Recent updates

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.

New major risk - Revenue and earnings growth

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

New minor risk - Share price stability

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

New major risk - Share price stability

Argenica Therapeutics Limited Announces Preclinical Data Shows ARG-007 Inhibits A Cause of Alzheimers

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Approves Commencement of Fourth and Final Cohort Dosing

Argenica Therapeutics Limited Announces That the First Subjects in the Third Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Dosed

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee (SRC) to Progress to the Third Escalated Dose Cohort

Less than half of directors are independent

Argenica Therapeutics Limited Announces Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee to Progress to the Second Escalated Dose Cohort

Argenica Therapeutics Limited Announces Healthy Participants in the First Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Successfully Dosed, Indicating Good Safety and Tolerability of ARG-007 in These Participants

Argenica Therapeutics Limited Announces First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

Argenica Therapeutics Limited Announces Further Positive Preclinical Results for ARG-007 in Hypoxic-Ischaemic Encephalopathy

Argenica Therapeutics Limited, Annual General Meeting, Nov 24, 2022

Argenica Therapeutics Limited Announces Phase 1 Clinical Trial Summary

Argenica Therapeutics Limited Receives Ethics Approval to Commence Phase 1 Trial

Argenica Therapeutics Limited Submits Application to Seek Approval to Commence Phase 1 Healthy Participant Study of ARG-007

Argenica Therapeutics Limited Appoints Dr. Jeffery Saver to Clinical Advisory Committee

Argenica Therapeutics Limited Announces Completion of the Final Pharmacokinetic (PK) Study of ARG-007 Required for the Phase 1 Clinical Trial

Less than half of directors are independent

Argenica Therapeutics Limited Announces Results of In-Life Rodent and Non-Human Primate Toxicology Studies Which Have Established the Maximum Tolerated Dose (MTD) of ARG-007

Less than half of directors are independent

Argenica Therapeutics Limited Announces Management Changes

Argenica Therapeutics Limited Announces Positive Preclincal Data on Efficacy of ARG-007

Argenica Therapeutics Limited Announces Successful Completion of Final GLP Genotoxicity Studies

Argenica Therapeutics Announces Completion of Preliminary Pre-Clinical Tox Studies

Argenica Therapeutics Limited Provides Additional Information of Study Shows ARG-007 Does Not Degrade

Argenica Therapeutics Limited Provides Positive Preliminary for ARG-007

Argenica Therapeutics Limited Completes Pilot Pre-Clinical Pharmacokinetics Study

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

マネジメント基準チェック /24